Price and clinical benefit of cancer drugs in Canada, 2011-2020

Cancer drug prices have increased exponentially in the past decade and several studies demonstrate an increasing disconnect between clinical benefit and prices for cancer drugs approved by the FDA or the EMA.1,2 This disconnect seemed to exist even in the setting of central price negotiations in Italy.3 However, this has not been studied for Canada. This study examines the association between approval characteristics, clinical benefit, and prices for cancer drugs recommended for reimbursement in Canada by the Canadian Agency for Drug and Technology in Health (CADTH).